{"prompt": "['relevant national or local health authorities, whichever is longer. After that period of time, the', 'documents may be destroyed, subject to local regulations.', '9.4.1', 'Independent Data Monitoring Committee', 'An iDMC will be assembled to review the safety data collected during the study. The iDMC', 'members will consist of, at minimum, independent hemostasis/thrombosis experts and', 'a', 'statistician, none of whom will be otherwise involved in the conduct of study. All analyses for', 'review by the iDMC will be prepared by the SMT statistician. Monitoring and analysis of all', 'significant safety events will be performed on a continuous basis. A first interim aAnalysis of', 'the study data will be performed once approximately 100 patients have received treatment', 'with emicizumab for at least 24 weeks (see Section 6.9.1), and a.A second interim analysis', 'will be performed when approximately 100 patients have received treatment with emicizumab', 'for at least 52 weeks. Thereafter, the iDMC will meet at a frequency determined by the iDMC', 'and the Sponsor according to the emerging data.', 'The SMT statistician will perform analyses and provide tables and listings to support the', 'study reviews by the iDMC. The safety data that will be provided will include demographic', 'data, adverse events (the incidence and severity of all adverse events, including', 'thromboembolic events, microangiopathic hemolytic anemia or TMA, systemic hypersensitivity,', 'anaphylaxis, and anaphylactoid events), medication dose information, physical examination', 'findings, vital sign data, and laboratory abnormalities (hematology and chemistry). If', 'available, the efficacy data that will provided will include the number of bleeds over time,', 'ABR data, the HRQoL of patients, the health status of patients according to EQ-5D-5L', 'scores, and patient preference for the emicizumab regimen compared with the previous', 'regimen used. Further information will be provided on request.', '9.7', 'STUDY PARTICIPANT SURVEY', 'Consenting patients may be asked about their study experience via a short study-specific survey.', 'Survey questions will ask the patient to rate their study experience on a scale of 1-5 on topics that', 'include the following: information provided prior to the study, the consent and enrolment process,', 'study participation, study results and feeling appreciated as a study patient.', 'Patients will be asked to complete the survey at the end of the study. The goal of this survey is to', 'identify areas where Roche is performing well and areas where improvement may be required.', 'Information will be provided to the Sponsor securely and on an anonymous basis and consent to the', \"survey is totally voluntary and does not affect patient's enrolment to the study.\", '10.', 'REFERENCES', 'Keizer RJ, Huitema ADR, Schellens JHM, Beijnen JH. Clinical pharmacokinetics of', 'therapeutic monoclona antibodies. Clin Pharmacokinet 2010;49:493 507.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '46 / Protocol MO39129, Version 3']['Mackensen SV, Gringeri A. Quality of life in hemophilia In: Preedy VR, Watson RR, editors.', 'Handbook of disease burdens and quality of life measures. Now York: Springer, 2010:1895', '920.', 'Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors.', 'NEJM 2017;277(9):809-18', 'Von Mackensen SV, Gringeri A. Quality of life in hemophilia. In: Preedy VR, Watson RR, editors.', 'Handbook of disease burdens and quality of life measures. New York: Springer, 2010:1895-920.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '47 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}